What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
His primary areas of investigation include Multiple sclerosis, Internal medicine, Immunology, Surgery and Placebo.
His Multiple sclerosis study combines topics in areas such as Central nervous system disease, Disease, Pathology, Intensive care medicine and Physical therapy.
His work deals with themes such as Gastroenterology, Expanded Disability Status Scale and Oncology, which intersect with Internal medicine.
His work in Immunology tackles topics such as Standardized mortality ratio which are related to areas like Retrospective cohort study.
The study incorporates disciplines such as Stroke, Spinal cord compression and Anesthesia in addition to Surgery.
His Placebo research is multidisciplinary, incorporating elements of Clinical endpoint, Randomized controlled trial, Clinical trial and Hazard ratio.
His most cited work include:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (1618 citations)
- Defining the clinical course of multiple sclerosis: The 2013 revisions (1374 citations)
What are the main themes of his work throughout his whole career to date?
Per Soelberg Sørensen mostly deals with Multiple sclerosis, Internal medicine, Immunology, Disease and Expanded Disability Status Scale.
In his study, White matter is inextricably linked to Pathology, which falls within the broad field of Multiple sclerosis.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Placebo, Surgery and Oncology.
Per Soelberg Sørensen interconnects Cladribine, Adverse effect, Randomized controlled trial and Clinical trial in the investigation of issues within Placebo.
As part of his studies on Immunology, Per Soelberg Sørensen often connects relevant subjects like Central nervous system.
His Natalizumab research includes elements of Fingolimod and Glatiramer acetate.
He most often published in these fields:
- Multiple sclerosis (65.18%)
- Internal medicine (33.18%)
- Immunology (21.88%)
What were the highlights of his more recent work (between 2017-2021)?
- Multiple sclerosis (65.18%)
- Internal medicine (33.18%)
- Disease (9.65%)
In recent papers he was focusing on the following fields of study:
Multiple sclerosis, Internal medicine, Disease, Expanded Disability Status Scale and Cladribine are his primary areas of study.
Per Soelberg Sørensen combines Multiple sclerosis and In patient in his studies.
The various areas that Per Soelberg Sørensen examines in his Internal medicine study include Placebo and Oncology.
His study in the fields of Demyelinating disease under the domain of Disease overlaps with other disciplines such as Multidisciplinary approach.
His Expanded Disability Status Scale study incorporates themes from Interquartile range, Cognition, Proportional hazards model, Propensity score matching and Hazard ratio.
His study in Cladribine is interdisciplinary in nature, drawing from both Magnetic resonance imaging, CLARITY and Immune system.
Between 2017 and 2021, his most popular works were:
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis: (199 citations)
- Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. (109 citations)
- ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. (67 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Per Soelberg Sørensen mainly investigates Multiple sclerosis, Internal medicine, Cladribine, Placebo and Confidence interval.
His studies in Multiple sclerosis integrate themes in fields like Clinical trial, Pharmacological treatment, Guideline, Intensive care medicine and Disease.
His studies deal with areas such as Dimethyl fumarate, Genotyping, Human leukocyte antigen and Interferon beta as well as Internal medicine.
The concepts of his Cladribine study are interwoven with issues in Immune system, Magnetic resonance imaging and Oncology.
His work carried out in the field of Placebo brings together such families of science as Gastroenterology and Randomized controlled trial.
Per Soelberg Sørensen has researched Confidence interval in several fields, including Expanded Disability Status Scale, Epidemiology, Proportional hazards model and Cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
